- In June 2025, Johnson & Johnson announced first results from the Phase 3 AMPLITUDE study, evaluating the combination of niraparib and abiraterone acetate plus prednisone (AAP) in patients with metastatic castration-sensitive prostate cancer (mCSPC) with homologous recombination repair (HRR) alterations. The study met its primary endpoint of radiographic progression-free survival (rPFS), showing a clinically meaningful and statistically significant improvement
- In June 2025, Scientists at The University of Texas Health Science Center at San Antonio (UT Health San Antonio) announced a significant discovery in June 2025 regarding a key DNA complex (CST complex) connected to PARP inhibitor resistance, opening doors for new strategies. In addition, studies are ongoing into PARP inhibitor rechallenge strategies, with promising results from trials such as KGOG 3056/NIRVANA-R (NCT04734665) presented at the 2025 SGO Annual Meeting on Women's Cancer
- In February 2025, A comprehensive review published reaffirmed Olaparib's leadership among PARP inhibitors in boosting overall survival for platinum-sensitive recurrent ovarian cancer, indicating its potential as a preferred option for patients
- In May 2024, The Re-VOLVE Phase II clinical trial (NCT05065021), presented in May 2025, investigates a chemo-free approach for women with ovarian cancer progressing post-PARP inhibitor treatment, adapting therapy to real-time assessment of evolving genomic resistance. This highlights the ongoing efforts to personalize PARP inhibitor treatment and address resistance
- In June 2023, Ariceum Therapeutics, a private biotech firm focused on radiopharmaceutical innovations for challenging cancers, announced its acquisition of Theragnostics Ltd. This UK-based biopharmaceutical company specializes in developing radio-labeled PARP inhibitors aimed at diagnosing and treating tumors. The acquisition is expected to enhance Ariceum's portfolio and accelerate advancements in targeted cancer therapies
